Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 51-53

  Valdezate, Sylvia ^a   Navarro, Ana ^a   Medina Pascual, María J ^a   Carrasco, Gema ^a   Saéz Nieto, Juan A ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Brucella spp.; Molecular typing; Resistance genes

Indexed keywords

ALANINE; BACTERIAL PROTEIN; CIPROFLOXACIN; DNA DIRECTED DNA POLYMERASE ALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; MOXIFLOXACIN; PROTEIN NORMI; PROTEIN NORMII; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BRUCELLA MELITENSIS; BRUCELLOSIS; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE;

EID: 77950349248     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp389     Document Type: Article

References (10)

1. Ariza J, Bosilkovski M, Cascio A et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med 2007; 4: e317.
2. Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother 2006; 50: 22-33.
3. Marianelli C, Ciuchini F, Tarantino M et al. Genetic bases of the rifampin resistance phenotype in Brucella spp. J Clin Microbiol 2004; 42: 5439-43.
4. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41: S120-6.
5. Turkmani A, Psaroulaki A, Christidou A et al. Uptake of ciprofloxacin and ofloxacin by 2 Brucella strains and their fluoroquinolone-resistant variants under different conditions. An in vitro study. Diagn Microbiol Infect Dis 2007; 59: 447-51.
6. Turkmani A, Psaroulaki A, Christidou A et al. In vitro-selected resistance to fluoroquinolones in two Brucella strains associated with mutational changes in gyrA. Int J Antimicrob Agents 2008; 32: 227-32.
7. Ravanel N, Gestin B, Maurin M. In vitro selection of fluoroquinolone resistance in Brucella melitensis. Int J Antimicrob Agents 2009; 34: 76-81.
8. García Lázaro FG, Rodríguez-Tarazona RE, García-Rodríguez JA et al. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro. Int J Antimicrob Agents 2009; 34: 252-4.
9. Al-Dahouk S, Le Flèche P, Nöckler K et al. Evaluation of Brucella MLVA typing for human brucellosis. J Microbiol Methods 2007; 69: 137-45.
10. Trujillano-Martín I, García-Sánchez E, Montes Martínez I et al. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 194-5.